BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23704110)

  • 1. Systemic inflammatory response syndrome in tissue-type plasminogen activator-treated patients is associated with worse short-term functional outcome.
    Boehme AK; Kapoor N; Albright KC; Lyerly MJ; Rawal PV; Bavarsad Shahripour R; Alvi M; Houston JT; Sisson A; Beasley TM; Alexandrov AW; Alexandrov AV; Miller DW
    Stroke; 2013 Aug; 44(8):2321-3. PubMed ID: 23704110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of systemic inflammatory response syndrome in ischemic stroke undergoing systemic thrombolysis with intravenous tissue plasminogen activator.
    Boehme AK; Kapoor N; Albright KC; Lyerly MJ; Rawal PV; Bavarsad Shahripour R; Alvi M; Houston JT; Sisson A; Beasley TM; Alexandrov AW; Alexandrov AV; Miller DW
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):e271-6. PubMed ID: 24424334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.
    Betts KA; Hurley D; Song J; Sajeev G; Guo J; Du EX; Paschoalin M; Wu EQ
    J Stroke Cerebrovasc Dis; 2017 Sep; 26(9):1996-2003. PubMed ID: 28689999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and continuous neurologic improvements after intravenous thrombolysis are strong predictors of favorable long-term outcomes in acute ischemic stroke.
    Yeo LL; Paliwal P; Teoh HL; Seet RC; Chan BP; Wakerley B; Liang S; Rathakrishnan R; Chong VF; Ting EY; Sharma VK
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):e590-6. PubMed ID: 23954601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of stroke patients receiving different doses of recombinant tissue plasminogen activator.
    Ong CT; Wong YS; Wu CS; Su YH
    Drug Des Devel Ther; 2017; 11():1559-1566. PubMed ID: 28572721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of admission hyperglycemia on stroke outcome in reperfused tissue plasminogen activator--treated patients.
    Alvarez-Sabín J; Molina CA; Montaner J; Arenillas JF; Huertas R; Ribo M; Codina A; Quintana M
    Stroke; 2003 May; 34(5):1235-41. PubMed ID: 12677014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous Tissue Plasminogen Activator for Wake-Up Stroke: A Propensity Score-Matched Analysis.
    Anaissie JE; Monlezun DJ; Siegler JE; Waring ED; Dowell LN; Samai AA; George AJ; Kimbrough T; Berthaud J; Martin-Schild S
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2603-2609. PubMed ID: 27476340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment diffusion-weighted imaging lesion volume predicts favorable outcome after intravenous thrombolysis with tissue-type plasminogen activator in acute ischemic stroke.
    Kruetzelmann A; Köhrmann M; Sobesky J; Cheng B; Rosenkranz M; Röther J; Schellinger PD; Ringleb P; Gerloff C; Fiehler J; Thomalla G
    Stroke; 2011 May; 42(5):1251-4. PubMed ID: 21415399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with tPA predicts better outcome even if MCA occlusion persists.
    Kablau M; Alonso A; Hennerici MG; Fatar M
    Int J Stroke; 2013 Oct; 8(7):496-502. PubMed ID: 22340025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke.
    Saposnik G; Fang J; Kapral MK; Tu JV; Mamdani M; Austin P; Johnston SC; ;
    Stroke; 2012 May; 43(5):1315-22. PubMed ID: 22308252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICU Interventions in Ischemic Stroke Patients Treated Using Liberalized IV-tPA Criteria.
    Murray NM; Ke M; Yee A; Chen C; Wong C; Bedenk A; Fernandes J; Barazangi N; Tong D
    J Stroke Cerebrovasc Dis; 2019 Sep; 28(9):2488-2495. PubMed ID: 31277995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The correlation between admission blood glucose and intravenous rt-PA-induced arterial recanalization in acute ischemic stroke: a multi-centre TCD study.
    Saqqur M; Shuaib A; Alexandrov AV; Sebastian J; Khan K; Uchino K
    Int J Stroke; 2015 Oct; 10(7):1087-92. PubMed ID: 26332252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials.
    Alexandrov AV; Schellinger PD; Saqqur M; Barreto A; Demchuk AM; Ribo M; Rubiera M; Sharma VK; Heliopoulos I; Alexandrov AW; Molina CA; Tsivgoulis G;
    Int J Stroke; 2011 Apr; 6(2):118-22. PubMed ID: 21371272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten-Year Evaluation of the TOYOTA Prehospital Stroke Scale for Tissue Plasminogen Activator Intravenous Therapy in the Real World.
    Suzuki J; Nakai N; Kondo N; Tsuji H; Inagaki R; Furukawa S; Iwata M; Nishida S; Ito Y
    Cerebrovasc Dis; 2018; 46(3-4):184-192. PubMed ID: 30384371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolytic therapy with intravenous recombinant tissue plasminogen activator in Japanese older patients with acute ischemic stroke: Fukuoka Stroke Registry.
    Matsuo R; Kamouchi M; Ago T; Hata J; Shono Y; Kuroda J; Wakisaka Y; Sugimori H; Kitazono T;
    Geriatr Gerontol Int; 2014 Oct; 14(4):954-9. PubMed ID: 24320947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Inflammation Indices in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator: Clinical Yield and Utility.
    Topcuoglu MA; Pektezel MY; Yilmaz E; Arsava EM
    Angiology; 2021 Mar; 72(3):279-284. PubMed ID: 33153275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic Inflammatory Response Syndrome and Outcomes in Intracerebral Hemorrhage.
    Boehme AK; Hays AN; Kicielinski KP; Arora K; Kapoor N; Lyerly MJ; Gadpaille A; Shiue H; Albright K; Miller D; Elkind MS; Harrigan MR
    Neurocrit Care; 2016 Aug; 25(1):133-40. PubMed ID: 26920909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging negative stroke: diagnoses and outcomes in intravenous tissue plasminogen activator-treated patients.
    Spokoyny I; Raman R; Ernstrom K; Meyer BC; Hemmen TM
    J Stroke Cerebrovasc Dis; 2014; 23(5):1046-50. PubMed ID: 24103663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Taking Warfarin with Subtherapeutic INR.
    Mowla A; Memon A; Razavi SM; Lail NS; Vaughn CB; Mohammadi P; Sawyer RN; Shirani P
    J Stroke Cerebrovasc Dis; 2021 May; 30(5):105678. PubMed ID: 33640783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue plasminogen activator thrombolytic therapy for acute ischemic stroke in 4 hospital groups in Japan.
    Kono S; Deguchi K; Morimoto N; Kurata T; Deguchi S; Yamashita T; Ikeda Y; Matsuura T; Narai H; Omori N; Manabe Y; Yunoki T; Takao Y; Kawata S; Kashihara K; Abe K
    J Stroke Cerebrovasc Dis; 2013 Apr; 22(3):190-6. PubMed ID: 21968092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.